Analyst ratings can significantly influence investor sentiment and stock prices. The downgrade from Buy to Hold reflects a shift in expectation towards a more neutral stance on Fusion Pharmaceuticals' near-term growth prospects. This could lead to a tempered reaction from the market as investors recalibrate their expectations based on this new analyst perspective.